Literature DB >> 28614203

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.

Kyra B Berg1, Andrew Churg.   

Abstract

The separation of sarcomatoid and desmoplastic malignant mesotheliomas from sarcomatoid carcinomas of the lung metastatic to the pleura may be difficult, since both types of tumor can be morphologically similar and are frequently positive only for pan-keratin. GATA binding protein 3 (GATA3) is most commonly used as an immunohistochemical marker of breast and urothelial carcinoma, but is also known to stain other types of tumors including some mesotheliomas. In this study we asked whether GATA3 stains could be used to distinguish sarcomatoid/desmoplastic malignant mesotheliomas (N=19) from sarcomatoid carcinomas of the lung (N=13). Tumor staining was scored for diffuseness and intensity, with a maximum possible score of 6. All 19 sarcomatoid/desmoplastic malignant mesotheliomas examined showed strong diffuse staining for GATA3 (no case scored <3, mean score±SD for all 19 cases 5.4±0.9), whereas only 2 of 13 sarcomatoid carcinomas of the lung stained positively for GATA3 and the staining was weak and patchy (score 2 for each case, mean±SD for all 13 cases 0.4±0.8). There was no correlation between the intensity and diffuseness of GATA-3 staining and staining for traditional mesothelioma markers. Overall, any positive staining for GATA3 was 100% sensitive and 85% specific for sarcomatoid/desmoplastic mesothelioma. We conclude that strong diffuse staining for GATA3 favors a diagnosis of sarcomatoid/desmoplastic malignant mesothelioma over metastatic sarcomatoid carcinoma of the lung; conversely, complete absence of GATA-3 staining is evidence against a diagnosis of sarcomatoid/desmoplastic malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28614203     DOI: 10.1097/PAS.0000000000000825

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 2.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

Review 3.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

Review 4.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

5.  Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b.

Authors:  Wei Wang; Mei Wang; Jing Xu; Fei Long; Xianbao Zhan
Journal:  Cancer Cell Int       Date:  2020-07-24       Impact factor: 5.722

6.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

7.  Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.

Authors:  Francoise Galateau Salle; Nolwenn Le Stang; Franck Tirode; Pierre Courtiol; Andrew G Nicholson; Ming-Sound Tsao; Henry D Tazelaar; Andrew Churg; Sanja Dacic; Victor Roggli; Daniel Pissaloux; Charles Maussion; Matahi Moarii; Mary Beth Beasley; Hugues Begueret; David B Chapel; Marie Christine Copin; Allen R Gibbs; Sonja Klebe; Sylvie Lantuejoul; Kazuki Nabeshima; Jean-Michel Vignaud; Richard Attanoos; Luka Brcic; Frederique Capron; Lucian R Chirieac; Francesca Damiola; Ruth Sequeiros; Aurélie Cazes; Diane Damotte; Armelle Foulet; Sophie Giusiano-Courcambeck; Kenzo Hiroshima; Veronique Hofman; Aliya N Husain; Keith Kerr; Alberto Marchevsky; Severine Paindavoine; Jean Michel Picquenot; Isabelle Rouquette; Christine Sagan; Jennifer Sauter; Francoise Thivolet; Marie Brevet; Philippe Rouvier; William D Travis; Gaetane Planchard; Birgit Weynand; Thomas Clozel; Gilles Wainrib; Lynnette Fernandez-Cuesta; Jean-Claude Pairon; Valerie Rusch; Nicolas Girard
Journal:  J Thorac Oncol       Date:  2020-03-09       Impact factor: 15.609

Review 8.  Circulating biomarkers in malignant pleural mesothelioma.

Authors:  Giuseppe Viscardi; Davide Di Natale; Morena Fasano; Marta Brambilla; Riccardo Lobefaro; Alessandro De Toma; Giulia Galli
Journal:  Explor Target Antitumor Ther       Date:  2020-12-28

Review 9.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02

10.  A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion.

Authors:  Rumeng Gu; Luxi Jiang; Ting Duan; Chun Chen; Shengchang Wu; Deguang Mu
Journal:  Onco Targets Ther       Date:  2021-07-16       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.